Ozempic & Heart Failure: Evidence-Based Clinical Overview

Last reviewed: May 19, 2026

Last updated: May 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists, including semaglutide (Ozempic), demonstrate cardiovascular benefit in specific heart failure phenotypes—particularly heart failure with preserved ejection fraction (HFpEF) combined with obesity. A 2023 NEJM study showed semaglutide reduced HFpEF hospitalizations by 21% in obese patients, but these outcomes vary significantly based on individual cardiac and metabolic factors.

Not all heart failure patients benefit equally from GLP-1 therapy. Clinical utility depends on ejection fraction, BMI, comorbid diabetes, and underlying metabolic dysfunction. PlexusDx precision-wellness approach integrates genetic and biomarker insights to help you and your provider evaluate whether GLP-1 therapy aligns with your cardiac and metabolic profile.

Heart Failure Phenotypes and GLP-1 Responsiveness

Heart failure manifests across a spectrum: reduced ejection fraction (HFrEF), preserved ejection fraction (HFpEF), and mildly reduced (HFmrEF). GLP-1 agonists show the strongest evidence in HFpEF, especially when obesity (BMI ≥30) coexists. The STEP-HFpEF trial demonstrated weight loss and functional improvement in this subgroup.

Patients with HFrEF and diabetes may benefit from GLP-1 therapy indirectly through improved glycemic control and weight reduction, yet the acute cardiac effects differ from HFpEF. Your heart failure phenotype—determined by ejection fraction and imaging—is essential context for evaluating whether GLP-1 therapy is appropriate for your situation.

Clinical Evidence: Key Trials and Outcomes

Multiple randomized trials clarify GLP-1 efficacy across heart failure subtypes. The STEP-HFpEF trial (2023) showed semaglutide reduced HFpEF hospitalizations by 21% and improved symptom burden. LEADER, SUSTAIN-6, and DECLARE trials documented cardiovascular event reduction in diabetes cohorts, though heart failure hospitalization endpoints varied by baseline ejection fraction and obesity status.

Trial / Data Point	Population	Key Finding
STEP-HFpEF (2023)	HFpEF + BMI ≥27	21% reduction in HF hospitalizations; weight loss ~9.2%
LEADER (semaglutide)	Type 2 diabetes	3-point MACE reduction; CV death benefit
SUSTAIN-6 (semaglutide)	Type 2 diabetes + CVD	26% MACE reduction; HF hosp variable by phenotype
DECLARE (dapagliflozin)	Type 2 diabetes ± CVD	SGLT2i data; combined HFpEF/HFrEF benefit seen

Biomarkers That Inform GLP-1 Candidacy

Beyond ejection fraction, biomarkers like NT-proBNP, troponin, and inflammatory markers (CRP, IL-6) help stratify heart failure severity and predict response. Obesity, insulin resistance, and metabolic syndrome amplify the benefit of GLP-1 therapy in HFpEF. Conversely, advanced renal dysfunction or severe volume overload may require priority optimization before GLP-1 initiation.

Genetic predispositions in metabolic pathways—such as FTO (fat mass and obesity-associated) variants and MC4R (melanocortin-4 receptor) polymorphisms—influence baseline metabolic phenotype and weight-loss response. These insights may help contextualize whether GLP-1 therapy aligns with your genetic and cardiometabolic risk profile.

Safety Considerations and Provider Guidance

GLP-1 agonists are generally well-tolerated in heart failure, but monitoring is essential. Volume status must be carefully managed; rapid weight loss can occasionally precipitate symptomatic hypotension or worsening renal function, especially in advanced heart failure. Gastrointestinal side effects and rare cases of acute pancreatitis require baseline assessment and ongoing surveillance.

A qualified cardiologist and primary care team should evaluate your ejection fraction, renal function, blood pressure, and current medications before initiating GLP-1 therapy. Compounded GLP-1 formulations available through PlexusDx require the same clinical oversight as branded options. Your provider will determine the appropriate starting dose, monitoring cadence, and adjustment strategy based on your individual cardiac status.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test reveals predispositions in key metabolic and peptide signaling pathways relevant to heart failure and GLP-1 response. Variants in GLP1R (rs6923761), FTO (rs9939609), MC4R (rs17782313), and GIPR (rs1800437) may help provide context on your baseline metabolic phenotype and potential weight-loss trajectory. These insights should be interpreted with your qualified healthcare provider as part of comprehensive cardiometabolic assessment.

The genetic test identifies predispositions in peptide signaling pathways—not exact medication response or heart failure risk. However, understanding your genetic background in obesity-related and GLP-1 receptor pathways can support a more personalized conversation about whether GLP-1 therapy aligns with your metabolic profile and heart failure phenotype. These results work best alongside standard biomarkers and imaging.

When considering GLP-1 therapy for heart failure, integrating genetic insights with clinical biomarkers, ejection fraction phenotype, and comorbidity burden creates a more complete picture. Your provider can use this context to assess candidacy, select appropriate formulations (including compounded options from PlexusDx), establish baseline monitoring, and track response over time.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.